UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group - PubMed (original) (raw)
Clinical Trial
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group
D R Matthews et al. Diabet Med. 1998 Apr.
Abstract
Patients with Type 2 (non-insulin-dependent) diabetes mellitus (DM) on sulphonylurea therapy convert to insulin progressively as the sulphonylureas 'fail'. The rate of failure and the features of those who fail have been poorly described. To assess secondary failure rates of sulphonylureas, we report on the responses in 1305 patients with newly diagnosed Type 2 DM randomly allocated to therapy with either chlorpropamide or glibenclamide in the UK Prospective Diabetes Study (UKPDS). These patients were initially treated by diet for 3 months and had a fasting plasma glucose > 6 mmol l(-1); mean age 53 (SD 9) years; BMI 26.8 (SD 5.0) kg m(-2); and median fasting plasma glucose 9.1 (7.6-12.5 quartiles) mmol l(-1). If their fasting plasma glucose subsequently rose above 15.0 mmol l(-1), or they developed hyperglycaemic symptoms, additional hypoglycaemic therapy was given: metformin, ultratard insulin, and soluble insulin as required. By 6 years, 44% had required additional therapy. Of those randomized to glibenclamide, 48% required additional therapy by 6 years, compared with 40% of those allocated to chlorpropamide (p < 0.01). Sixty-one per cent, 39%, and 23%, respectively, of patients with fasting plasma glucose > or = 10.0 mmol l(-1), > or = 7.8 mmol l(-1) to < 10.0 mmol l(-1) and < 7.8 mmol l(-1) at randomization required additional therapy (p < 0.001). In the initial 3 years, non-obese subjects (BMI < 30 kg m(-2)) were more likely to require additional therapy than obese patients (BMI > or = 30 kg m(-2)) (43% vs 53% at 6 years; p < 0.001). Modelled beta-cell function showed that those with lower function were more likely to fail (p < 0.0001). Thus sulphonylureas fail as a therapeutic agent at rates which are dependent both on the phenotype at presentation and perhaps on the agent used initially. Higher failure rates were found in those with higher glucose concentrations, those who were younger, those with lower beta-cell reserve and those randomized to glibenclamide compared with chlorpropamide.
Similar articles
Cited by
- Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines.
Schwartz SS, Corkey BE, R Gavin J 3rd, DeFronzo RA, Herman ME. Schwartz SS, et al. BMC Med. 2024 Sep 4;22(1):356. doi: 10.1186/s12916-024-03518-5. BMC Med. 2024. PMID: 39227924 Free PMC article. Review. - The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah.
Li N, Panchal R, Giannouchos T, Pan RJ, Nguyen D, Nohavec R, Britton L, Chaiyakunapruk N, Biskupiak J, Wilson A, Brixner D. Li N, et al. J Manag Care Spec Pharm. 2024 Feb 3;30(2):112-117. doi: 10.18553/jmcp.2024.30.2.112. J Manag Care Spec Pharm. 2024. PMID: 38308630 Free PMC article. - Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, DeSouza C, DeFronzo RA, Elasy T, Krakoff J, Kahn SE, Rasouli N, Valencia WM, Sivitz WI; GRADE Research Group. Utzschneider KM, et al. Diabetes Care. 2024 Apr 1;47(4):571-579. doi: 10.2337/dc23-1059. Diabetes Care. 2024. PMID: 38190619 Clinical Trial. - Antihyperglycemic and anti-type 2 diabetic activity of marine hydroquinone isolated from brown algae (Dictyopteris polypodioides).
Truong TPT, Tran TM, Dai TXT, Tran CL. Truong TPT, et al. J Tradit Complement Med. 2023 Mar 20;13(4):408-416. doi: 10.1016/j.jtcme.2023.03.007. eCollection 2023 Jul. J Tradit Complement Med. 2023. PMID: 37396160 Free PMC article. - Trends of clinical parameters and incidences of diabetes mellitus complications among patients with type 2 diabetes mellitus in Hong Kong, 2010-2019: a retrospective cohort study.
Wang Y, Xu W, Mak IL, Chin WY, Yu EYT, Lam CLK, Wan EYF. Wang Y, et al. EClinicalMedicine. 2023 May 11;60:101999. doi: 10.1016/j.eclinm.2023.101999. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37234549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical